Brainstorm Cell Therapeutics Inc. (BCLI) Ownership
BCLI ownership summary
as of October 21, 2026- Institutions
- 0.0% of shares outstanding
- Insiders
- 8.68% of shares outstanding
- Shares outstanding
- 11.0M
- Float
- 10.3M shares available to trade
- Short interest
- 6.05% 604K shares short
- Days to cover
- 1.30 short interest up 30.5% vs prior month
- Insiders 8.68%
- Other investors 91.32%
BCLI top institutional holders
6 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BNP Paribas Arbitrage, SA | 0.00% | — | — | −24 (−100.0%) | December 31, 2025 |
| 2 | VSM Wealth Advisory, LLC | 0.00% | — | — | −120 (−100.0%) | December 31, 2025 |
| 3 | Advisor Group Holdings, Inc. | 0.00% | — | — | −1,785 (−100.0%) | December 31, 2025 |
| 4 | St Germain D J Co Inc | 0.00% | — | — | −33 (−100.0%) | December 31, 2025 |
| 5 | Steward Partners Investment Advisory, LLC | 0.00% | — | — | −113 (−100.0%) | December 31, 2025 |
| 6 | Bangor Savings Bank | 0.00% | — | — | −266 (−100.0%) | December 31, 2025 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 6, 0 holders added 0 shares and 6 cut 2,341.
BCLI top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Extended Equity Market Fund B | 0.04% | 4,799 | $3,695 | +4,799 (0.0%) | June 30, 2025 |
Funds report holdings monthly or quarterly; dates differ by fund.
BCLI insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-09-30 | Chaim Lebovits | Buy | $3.45 | 1,466 | $5,058 |
| 2024-07-19 | Ibrahim B. Dagher | Sell | $5.25 | 4,200 | $22,050 |
| 2023-09-01 | Stacy Lindborg | Buy | $26.55 | 766 | $20,337 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
BCLI shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns BCLI
Institutional investors own 0.0% of Brainstorm Cell Therapeutics's shares and insiders 8.68%. The largest holder is BNP Paribas Arbitrage, SA with 0.00% of the shares (0), as of December 31, 2025. Among the top 6 institutions, 0 added shares and 6 reduced their stake in the latest filings. Short interest is 6.05% of the float, or 1.30 days of average trading volume. The share count rose 810.7% since 2014.
Related: BCLI analyst forecast, BCLI key metrics. See the BCLI stock overview for the latest quote and news.
BCLI ownership FAQ
Who owns the most Brainstorm Cell Therapeutics stock?
The largest shareholders of Brainstorm Cell Therapeutics are BNP Paribas Arbitrage, SA (0.00%), VSM Wealth Advisory, LLC (0.00%), Advisor Group Holdings, Inc. (0.00%), St Germain D J Co Inc (0.00%), Steward Partners Investment Advisory, LLC (0.00%).
What percentage of Brainstorm Cell Therapeutics is owned by institutions?
Institutions hold 0.0% of Brainstorm Cell Therapeutics's shares outstanding; insiders hold 8.68%.
Which funds own Brainstorm Cell Therapeutics?
The largest fund holders of Brainstorm Cell Therapeutics are Extended Equity Market Fund B (0.04%).
What is Brainstorm Cell Therapeutics's short interest?
604K shares of Brainstorm Cell Therapeutics were sold short, 6.05% of the float; at the average daily volume it would take 1.30 days to cover.
Are insiders buying or selling Brainstorm Cell Therapeutics?
Of the latest 3 reported insider transactions in Brainstorm Cell Therapeutics (since September 1, 2023), 2 were purchases and 1 were sales.
How many shares of Brainstorm Cell Therapeutics are outstanding?
Brainstorm Cell Therapeutics has 11.0M shares outstanding, of which 10.3M are in the public float.